Summary
3H-ouabain was administered intravenously to control patients, and to patients suffering from liver disease or renal failure. In the control patients the 3H-ouabain disappeared from the serum by two exponentials, with half-lives of about 20 min and 50 h, respectively. After 5–6 h only 8% of the initial serum concentration remained. During 48 h following drug administration about 61 % of the administered dose was excreted in the urine. 3H-ouabain was excreted as such and not metabolized. Liver disease accompanied by pathological impairment of bile production neither affected the disappearance from the serum nor the urinary excretion. During renal failure, however, only 28% of the administered 3H-ouabain was excreted with the urine during 48h. The serum level was 2–3 times higher than in the control patients.
Zusammenfassung
3H-g-Strophanthin wurde Patienten folgender drei Kategorien i.v. verabreicht: a) Kontrollpatienten b) Patienten mit eingeschränkter Leberfunktion (Cirrhose, Verschlußikterus) c) Patienten mit eingeschrankter Nierenfunktion (Pyelonephritis, Glomerulonephritis).. Bei den Kontrollpatienten nahm der Serumspiegel mit zwei Zeitkonstanten ab (t 1/2 20 min bzw. etwa 50 Std). 5–6 Std nach der Injektion betrug die Serumkonzentration nur noch 10% des Ausgangswertes. Nach 48 Std waxen etwa 61% der verabreichten Dosis mit dem Urin ausgeschieden worden. 3H-g-Strophanthin wurde in unveranderter Form eliminiert. Bei Leberkranken mit eingeschrankter Galleproduktion zeigte der zeitliche Verlauf des Serumspiegels und die Urinausscheidung dasselbe Verhalten wie bei den Kontrollpatienten. Von den nierenerkrankten Patienten dagegen worden in 48 Std nur 28% des verabreichten 3H-g-Strophanthin mit dem Urin ausgeschieden. Die Serumradioaktivität lag 6–48 Std nach der Injektion des Glykosids 2–3 mal so hoch wie bei den Kontrollen.
Similar content being viewed by others
References
Doherty, J.E., and W.J. Flanigan: Studies with tritiated digoxin in anephric human subjects. Circulation 35, 298–302 (1967).
—, and W. H. Perkins: Studies with tritiated digoxin in human subjects after intravenous administration. Amer. Heart J. 63, 528–536 (1962).
—, — Studies following intramuscular tritiated digoxin in human subjects. Amer. J. Cardiol. 15, 170–174 (1965).
—, — Digoxin metabolism in hypo- and hyperthyroidism. Ann. intern. Med. 64, 489–507 (1966).
—, — and W. J. Flanigan: The distribution and concentration of tritiated digoxin in human tissues. Ann. Int. Med. 66, 116–124 (1967).
—, — and G. K. Mitchell: Tritiated digoxin studies in human subjects. Arch. intern. Med. (Chicago) 108, 531–539 (1961).
—, — and M.C. Wilson: Studies with tritiated digoxin in renal failure. Amer. J. Med. 37, 536–543 (1964).
Kuschinsky, K.: Bestimmung der Eiweißbindung verschiedener Herzglykoside mittels SephadexR-Gelfil-tration. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 259, 394–399 (1968).
—, H. Lüllmann, and P.A. Van Zwieten: A comparison of the accumulation and release of 3H-ouabain and 3H-digitoxin by guinea pig heart muscle. Brit. J. Pharmacol. 32, 598–608 (1968).
Lahrtz, HG., and P. A. Van Zwieten: The influence of kidney or liver disorders on the serum concentration and urinary excretion of 3H-peruvoside, a tritium-labelled cardiac glycoside. Europ. J. Pharmacol. 3, 147–152 (1968).
Marcus, F.I., A. S. Peterson, A. F. Sadel, J. Scully, and G. Kapadia: The metabolism of tritiated digoxin in renal insufficiency in dogs and man. J. Pharmacol. exp. Ther. 152, 372–382 (1966).
Marks, B.H., S. Dutta, J. Gauthier, and D. Elliott: Distribution in plasma, uptake by the heart and excretion of ouabain-3H in human subjects. J. Pharmacol. exp. Ther. 145, 351–356 (1964).
Okita, G. T., P. J. Talso, J. H. Curry, E. D. Smith, and E.M.K. Geiling: Metabolic fate of radioactive digitoxin in human subjects. J. Pharmacol. exp. Ther. 115, 371–379 (1955).
Van Zwieten, P.A.: Über die Gewebsverteilung, den Metabolismus und die Ausscheidung von Herzglykosiden. Dtsch. med. Wschr. 92, 1684–1687 (1967).
Author information
Authors and Affiliations
Additional information
Part of the results have been presented as a short communication at the Spring Meeting of the Deutsche Pharmakologische Gesellschaft, Mainz, March 1968.
Rights and permissions
About this article
Cite this article
Lahrtz, H., Reinold, H.M. & van Zwieten, P.A. Serum concentration and urinary excretion of 3H-Ouabain in patients suffering from liver or kidney diseases. Pharmacol. Clin. 1, 114–118 (1969). https://doi.org/10.1007/BF00404656
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00404656